| SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition A Nelde, T Bilich, JS Heitmann, Y Maringer, HR Salih, M Roerden, ... Nature immunology 22 (1), 74-85, 2021 | 617 | 2021 |
| A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity JS Heitmann, T Bilich, C Tandler, A Nelde, Y Maringer, M Marconato, ... Nature 601 (7894), 617-622, 2022 | 201 | 2022 |
| T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals T Bilich, A Nelde, JS Heitmann, Y Maringer, M Roerden, J Bauer, J Rieth, ... Science translational medicine 13 (590), eabf7517, 2021 | 164 | 2021 |
| The peptide vaccine of the future A Nelde, HG Rammensee, JS Walz Molecular & cellular proteomics 20, 2021 | 148 | 2021 |
| The antigenic landscape of multiple myeloma: mass spectrometry (re) defines targets for T-cell–based immunotherapy S Walz, JS Stickel, DJ Kowalewski, H Schuster, K Weisel, L Backert, ... Blood, The Journal of the American Society of Hematology 126 (10), 1203-1213, 2015 | 121 | 2015 |
| Magnetic bead-based immunoassay allows rapid, inexpensive, and quantitative detection of human SARS-CoV-2 antibodies LF Huergo, KA Selim, MS Conzentino, ECM Gerhardt, ARS Santos, ... ACS sensors 6 (3), 703-708, 2021 | 77* | 2021 |
| Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity M Becker, M Strengert, D Junker, PD Kaiser, T Kerrinnes, B Traenkle, ... Nature communications 12 (1), 1152, 2021 | 73 | 2021 |
| The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy T Bilich, A Nelde, L Bichmann, M Roerden, HR Salih, DJ Kowalewski, ... Blood, The Journal of the American Society of Hematology 133 (6), 550-565, 2019 | 70 | 2019 |
| Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination Y Maringer, A Nelde, SM Schroeder, J Schuhmacher, S Hörber, A Peter, ... Science immunology 7 (78), eadd3899, 2022 | 59 | 2022 |
| Purification and identification of naturally presented MHC class I and II ligands A Nelde, DJ Kowalewski, S Stevanović Antigen Processing: Methods and Protocols, 123-136, 2019 | 57 | 2019 |
| NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies TR Wagner, E Ostertag, PD Kaiser, M Gramlich, N Ruetalo, D Junker, ... EMBO reports 22 (5), e52325, 2021 | 53 | 2021 |
| HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell … A Nelde, DJ Kowalewski, L Backert, H Schuster, JO Werner, R Klein, ... Oncoimmunology 7 (4), e1316438, 2018 | 49 | 2018 |
| Preexisting and post–COVID-19 immune responses to SARS-CoV-2 in patients with cancer T Bilich, M Roerden, Y Maringer, A Nelde, JS Heitmann, ML Dubbelaar, ... Cancer discovery 11 (8), 1982-1995, 2021 | 43 | 2021 |
| MHCquant: automated and reproducible data analysis for immunopeptidomics L Bichmann, A Nelde, M Ghosh, L Heumos, C Mohr, A Peltzer, ... Journal of proteome research 18 (11), 3876-3884, 2019 | 43 | 2019 |
| Integrative-omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy A Reustle, M Di Marco, C Meyerhoff, A Nelde, JS Walz, S Winter, ... Genome medicine 12, 1-24, 2020 | 41 | 2020 |
| Targeting self-and neoepitopes with a modular self-adjuvanting cancer vaccine E Belnoue, JF Mayol, S Carboni, WDB Besson, E Dupuychaffray, A Nelde, ... JCI insight 4 (11), 2019 | 40 | 2019 |
| HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy A Nelde, JS Walz, DJ Kowalewski, H Schuster, OO Wolz, JK Peper, ... Oncoimmunology 6 (3), e1219825, 2017 | 37 | 2017 |
| Guidance document: validation of a high-performance liquid chromatography-tandem mass spectrometry immunopeptidomics assay for the identification of HLA class I ligands … M Ghosh, M Gauger, A Marcu, A Nelde, M Denk, H Schuster, ... Molecular & Cellular Proteomics 19 (3), 432-443, 2020 | 35 | 2020 |
| The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma J Bauer, N Köhler, Y Maringer, P Bucher, T Bilich, M Zwick, S Dicks, ... Nature Communications 13 (1), 6401, 2022 | 29 | 2022 |
| Immunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia A Nelde, Y Maringer, T Bilich, HR Salih, M Roerden, JS Heitmann, ... Frontiers in immunology 12, 705974, 2021 | 29 | 2021 |
Juliane WalzCCU Translational Immunology, Medical Department and Department of Immunology, University and在 med.uni-tuebingen.de 的电子邮件经过验证
